These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 7536492)

  • 1. Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry.
    Guerci A; Merlin JL; Missoum N; Feldmann L; Marchal S; Witz F; Rose C; Guerci O
    Blood; 1995 Apr; 85(8):2147-53. PubMed ID: 7536492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anthracycline drugs and MDR expression in human leukemia.
    Pogliani EM; Belotti D; Rivolta GF; Maffè PF; Corneo G
    Cytotechnology; 1996; 19(3):229-35. PubMed ID: 8862011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia.
    List AF; Spier CS; Grogan TM; Johnson C; Roe DJ; Greer JP; Wolff SN; Broxterman HJ; Scheffer GL; Scheper RJ; Dalton WS
    Blood; 1996 Mar; 87(6):2464-9. PubMed ID: 8630412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of the expression of P glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat shock protein 27 on response to induction therapy and long-term survival in patients with de novo acute myeloid leukemia.
    Kasimir-Bauer S; Beelen D; Flasshove M; Noppeney R; Seeber S; Scheulen ME
    Exp Hematol; 2002 Nov; 30(11):1302-8. PubMed ID: 12423683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia.
    Tsimberidou AM; Paterakis G; Androutsos G; Anagnostopoulos N; Galanopoulos A; Kalmantis T; Meletis J; Rombos Y; Sagriotis A; Symeonidis A; Tiniakou M; Zoumbos N; Yataganas X
    Leuk Res; 2002 Feb; 26(2):143-54. PubMed ID: 11755464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia.
    te Boekhorst PA; Löwenberg B; van Kapel J; Nooter K; Sonneveld P
    Leukemia; 1995 Jun; 9(6):1025-31. PubMed ID: 7541095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia.
    Sievers EL; Lange BJ; Alonzo TA; Gerbing RB; Bernstein ID; Smith FO; Arceci RJ; Woods WG; Loken MR
    Blood; 2003 May; 101(9):3398-406. PubMed ID: 12506020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P-glycoprotein expression and prognostic value in acute myeloid leukemia.
    Senent L; Jarque I; Martín G; Sempere A; González-García Y; Gomis F; Pérez-Sirvent M; De La Rubia J; Sanz MA
    Haematologica; 1998 Sep; 83(9):783-7. PubMed ID: 9825574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new PCR MIMIC strategy to quantify low mdr1 mRNA levels in drug resistant cell lines and AML blast samples.
    Illmer T; Schaich M; Oelschlägel U; Nowak R; Renner U; Ziegs B; Subat S; Neubauer A; Ehninger G
    Leuk Res; 1999 Jul; 23(7):653-63. PubMed ID: 10400187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P-glycoprotein and multidrug resistance-associated protein, but not lung resistance protein, lower the intracellular daunorubicin accumulation in acute myeloid leukaemic cells.
    Borg AG; Burgess R; Green LM; Scheper RJ; Liu Yin JA
    Br J Haematol; 2000 Jan; 108(1):48-54. PubMed ID: 10651723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FAB M4 and high CD14 surface expression is associated with high cellular resistance to Ara-C and daunorubicin: implications for clinical outcome in acute myeloid leukaemia.
    Nørgaard JM; Olesen LH; Olesen G; Meyer K; Kristensen JS; Bendix K; Pedersen B; Kjeldsen E; Hokland P
    Eur J Haematol; 2001 Oct; 67(4):221-9. PubMed ID: 11860442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study of apoptosis-related responses of leukemic blast cells to in vitro anthracycline treatment.
    Belaud-Rotureau MA; Durrieu F; Labroille G; Lacombe F; Fitoussi O; Agape P; Marit G; Reiffers J; Belloc F
    Leukemia; 2000 Jul; 14(7):1266-75. PubMed ID: 10914552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low frequency of activity of P-glycoprotein (P-170) in acute lymphoblastic leukemia compared to acute myeloid leukemia.
    Ludescher C; Eisterer W; Hilbe W; Gotwald M; Hofmann J; Zabernigg A; Cianfriglia M; Thaler J
    Leukemia; 1995 Feb; 9(2):350-6. PubMed ID: 7869774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between CD34 expression and chromosomal abnormalities but not clinical outcome in acute myeloid leukemia.
    Fruchart C; Lenormand B; Bastard C; Boulet D; Lesesve JF; Callat MP; Stamatoullas A; Monconduit M; Tilly H
    Am J Hematol; 1996 Nov; 53(3):175-80. PubMed ID: 8895688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Predictive value of intracellular accumulation of daunorubicin and P-glycoprotein expression simultaneously determined by flow cytometry in adult acute myeloid leukemias].
    Guerci A; Merlin JL; Missoum N; Feldmann L; Marchal S; Guerci O
    Ann Biol Clin (Paris); 1996; 54(1):17-9. PubMed ID: 8731790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression and functional activity of P-glycoprotein in adult acute myelogenous leukemia patients.
    Nuessler V; Gullis E; Pelka-Fleischer R; del Valle F; Diem H; Beyerlein S; Zwierzina H; Wilmanns W
    Ann Hematol; 1997; 75(1-2):17-26. PubMed ID: 9322679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia.
    Schuurhuis GJ; Broxterman HJ; Ossenkoppele GJ; Baak JP; Eekman CA; Kuiper CM; Feller N; van Heijningen TH; Klumper E; Pieters R
    Clin Cancer Res; 1995 Jan; 1(1):81-93. PubMed ID: 9815890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+ acute myeloid leukemia cells.
    te Boekhorst PA; de Leeuw K; Schoester M; Wittebol S; Nooter K; Hagemeijer A; Löwenberg B; Sonneveld P
    Blood; 1993 Nov; 82(10):3157-62. PubMed ID: 7693039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro drug resistance in acute myeloid and chronic B-lymphocytic leukaemic blasts and in normal blood and marrow populations.
    Baines P; Limaye M; Hoy T; Padua RA; Whittaker J; al-Sabah A; Burnett A
    Leuk Res; 1994 Sep; 18(9):683-91. PubMed ID: 7934144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia--analysis of 848 patients.
    Visani G; Bernasconi P; Boni M; Castoldi GL; Ciolli S; Clavio M; Cox MC; Cuneo A; Del Poeta G; Dini D; Falzetti D; Fanin R; Gobbi M; Isidori A; Leoni F; Liso V; Malagola M; Martinelli G; Mecucci C; Piccaluga PP; Petti MC; Rondelli R; Russo D; Sessarego M; Specchia G; Testoni N; Torelli G; Mandelli F; Tura S
    Leukemia; 2001 Jun; 15(6):903-9. PubMed ID: 11417475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.